Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DFA7 | ISIN: KY61559X1045 | Ticker-Symbol:
NASDAQ
01.04.25
21:47 Uhr
37,030 US-Dollar
-2,000
-5,12 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOONLAKE IMMUNOTHERAPEUTICS Chart 1 Jahr
5-Tage-Chart
MOONLAKE IMMUNOTHERAPEUTICS 5-Tage-Chart

Aktuelle News zur MOONLAKE IMMUNOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.03.BTIG maintains Moonlake stock Buy rating and $81 target1
MOONLAKE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln
18.03.MoonLake earns new Outperform at RBC Capital Markets on lead drug4
12.03.Cowen maintains Buy on Moonlake Immunotherapeutics stock1
26.02.MoonLake Immunotherapeutics reports Q4 results3
26.02.MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update289Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis...
► Artikel lesen
26.02.MoonLake Immunotherapeutics - 10-K, Annual Report1
26.02.MoonLake Immunotherapeutics - 8-K, Current Report1
16.01.MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset4
08.01.MoonLake Immunotherapeutics AG: MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody sonelokimab394New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar...
► Artikel lesen
20.12.24MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 3.2% - What's Next?1
18.12.24MoonLake Immunotherapeutics - 8-K, Current Report-
13.11.24MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis376MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing...
► Artikel lesen
07.11.24MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update297MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable...
► Artikel lesen
07.11.24MoonLake Immunotherapeutics - 10-Q, Quarterly Report1
07.11.24MoonLake Immunotherapeutics - 8-K, Current Report2
15.10.24H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares2
07.10.24MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 8.3% - Time to Sell?2
09.09.24MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11747MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 - MoonLake Immunotherapeutics AG ("MoonLake"; Nasdaq: MLTX), a clinical-stage...
► Artikel lesen
07.08.24MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11388MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in hidradenitis...
► Artikel lesen
24.06.24DelveInsight Business Research, LLP: Psoriasis Market to Register Incremental Growth by 2034, Predicts DelveInsight | Key Companies - AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb, Amgen, Dermavant Sciences956DelveInsight's analysts estimate that the psoriasis market is poised to show significant growth, mainly attributed to increasing prevalence, recent drug approvals, and anticipated launch...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1